Detailed information for compound 1880257

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 668.611 | Formula: C37H35Cl2N5O3
  • H donors: 3 H acceptors: 2 LogP: 8.86 Rotable bonds: 15
    Rule of 5 violations (Lipinski): 2
  • SMILES: COC(=O)/C(=C/c1ccc(cc1)Oc1ccc(cc1)N/C(=N/c1ccc(cc1)Cl)/NCCCCNc1ccnc2c1ccc(c2)Cl)/C
  • InChi: 1S/C37H35Cl2N5O3/c1-25(36(45)46-2)23-26-5-14-31(15-6-26)47-32-16-12-30(13-17-32)44-37(43-29-10-7-27(38)8-11-29)42-21-4-3-20-40-34-19-22-41-35-24-28(39)9-18-33(34)35/h5-19,22-24H,3-4,20-21H2,1-2H3,(H,40,41)(H2,42,43,44)/b25-23+
  • InChiKey: MMCKQPFCJBSWCF-WJTDDFOZSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Plasmodium vivax proteasome subunit beta type-5, putative 0.00628539 1 1
Mycobacterium leprae proteasome (beta subunit) PrcB 0.00628539 1 0.5
Toxoplasma gondii proteasome subunit beta type, putative 0.00628539 1 1
Plasmodium falciparum proteasome subunit beta type-5 0.00628539 1 1
Leishmania major proteasome beta 5 subunit, putative 0.00628539 1 1
Mycobacterium tuberculosis Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. 0.00628539 1 0.5
Giardia lamblia Proteasome subunit beta type 5 precursor 0.00628539 1 1
Loa Loa (eye worm) proteasome A-type and B-type family protein 0.00628539 1 1
Trypanosoma cruzi proteasome subunit beta type-5, putative 0.00628539 1 1
Trypanosoma brucei proteasome subunit beta type-5, putative 0.00628539 1 1
Trichomonas vaginalis Family T1, proteasome beta subunit, threonine peptidase 0.00628539 1 1
Trypanosoma cruzi proteasome subunit beta type-5, putative 0.00628539 1 1
Echinococcus granulosus proteasome prosome macropain 0.00628539 1 1
Brugia malayi Proteasome A-type and B-type family protein 0.00628539 1 1
Echinococcus multilocularis proteasome (prosome, macropain) 0.00628539 1 1
Entamoeba histolytica proteasome subunit beta type 5 precursor, putative 0.00628539 1 1
Schistosoma mansoni proteasome catalytic subunit 3 (T01 family) 0.00628539 1 1
Mycobacterium ulcerans proteasome PrcB 0.00628539 1 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (functional) = 56.37 nM Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected after 72 hrs by Malaria SYBR Green I-staining based fluorescence assay ChEMBL. 24630564
IC50 (functional) = 715.8 nM Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected after 72 hrs by Malaria SYBR Green I-staining based fluorescence assay ChEMBL. 24630564
MIC (functional) = 6.25 ug ml-1 Antifungal activity against Candida albicans clinical isolate after 24 to 48 hrs by standard broth microdilution method ChEMBL. 24630564
MIC (functional) = 6.25 ug ml-1 Antifungal activity against Cryptococcus neoformans clinical isolate after 24 to 48 hrs by standard broth microdilution method ChEMBL. 24630564
MIC (functional) = 25 ug ml-1 Antimicrobial activity against Escherichia coli ATCC 9637 after 24 hrs by standard broth microdilution method ChEMBL. 24630564

Phenotypes

Whole-cell/tissue/organism interactions

Species name Source Reference Is orphan
Plasmodium falciparum 24630564

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.